Abstract:Anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis is an autoimmune encephalitis that was reported in recent years. At present, there remains no unified treatment regimen for the children and adolescents with this disease around the world. Immunotherapy is still the preferred way of treatment, mainly including first-line immunotherapy, second-line immunotherapy, and long-term immunotherapy. In recent years, some researchers have tried new immunosuppressants or modified immunotherapy regimens to improve the treatment outcome of the patients. This article summarizes related immunotherapy regimens, as well as the future direction of research on immunotherapy for anti-NMDAR encephalitis.